{Reference Type}: Published Erratum
{Title}: [Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple‑negative breast cancer through the regulation of pyroptosis.
{Author}: Lei S;Li S;Xiao W;Jiang Q;Yan S;Xiao W;Cai J;Wang J;Zou L;Chen F;Liu Y;Jiang Y;
{Journal}: Oncol Rep
{Volume}: 51
{Issue}: 3
{Year}: 2024 Mar
{Factor}: 4.136
{DOI}: 10.3892/or.2024.8708
{Abstract}: Following the publication of the above article, the authors drew to our attention that they had made a couple of inadvertent errors in assembling Figs. 4 and 5; first, for the BT‑549 cell line, the data shown for the Pro‑caspase‑1/Cleaved caspase‑1 in Fig. 5 and the GSDMD‑F/GSDMD‑N data in Fig. 4B were identical, and had been derived from the same original source; secondly, in Fig. 4A, the data shown correctly for the GSDMD BT‑549 cell line had also inadvertently been included in this figure to represent the MDA‑MB‑231 cell line. The revised and corrected versions of Figs. 4 and 5, showing the correct western blotting data for the GSDMD experiment in Fig. 4A and the Pro‑caspase‑1/Cleaved caspase‑1 data for the BT‑549 cell line in Fig. 5, are shown in the next two pages. The authors regret that these errors in the assembly of Figs. 4 and 5 went unnoticed before the article was published, and thank the Editor of Oncology Reports for granting them the opportunity to publish this corrigendum. All the authors agree with the publication of this corrigendum; furthermore, they apologize to the readership of the journal for any inconvenience caused.[Oncology Reports 50: 188, 2023; DOI: 10.3892/or.2023.8625].